Changing thresholds and incidence of antibiotic treatment of cystic fibrosis pulmonary exacerbations, 1995-2005

Journal of Cystic Fibrosis

Volumn 12, Issue 4, 2013, Pages 332-337

  VanDevanter, Donald R ^a   Elkin, Eric P ^b   Pasta, David J ^b   Morgan, Wayne J ^c   Konstan, Michael W ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ICON Late Phase and Outcomes Research   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

Author keywords

Cystic fibrosis; Epidemiology; Pulmonary exacerbation; Treatment thresholds

Indexed keywords

ADOLESCENT; ADULT; ANTIBIOTIC THERAPY; ARTICLE; CHILD; CONTROLLED STUDY; CYSTIC FIBROSIS; DIFFERENTIAL THRESHOLD; DISEASE EXACERBATION; GROUPS BY AGE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY;

ADOLESCENT; ANTI-BACTERIAL AGENTS; CHILD; CYSTIC FIBROSIS; DISEASE PROGRESSION; DRUG PRESCRIPTIONS; HUMANS;

EID: 84878346897     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2012.11.011     Document Type: Article

References (32)

1. Ouyang L., Grosse S.D., Amendah D.D., Schechter M.S. Healthcare expenditures for privately insured people with cystic fibrosis. Pediatr Pulmonol 2009, 44:989-996.
2. Orenstein D.M., Pattishall E.N., Nixon P.A., Ross E.A., Kaplan R.M. Quality of well-being before and after antibiotic treatment of pulmonary exacerbation in patients with cystic fibrosis. Chest 1990, 98:1081-1084.
3. Bradley J., McAlister O., Elborn S. Pulmonary function, inflammation, exercise capacity and quality of life in cystic fibrosis. Eur Respir J 2001, 17:712-715.
4. Britto M.T., Kotagal U.R., Hornung R.W., Atherton H.D., Tsevat J., Wilmott R.W. Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis. Chest 2002, 121:64-72.
5. Ferkol T., Rosenfeld M., Milla C.E. Cystic fibrosis pulmonary exacerbations. J Pediatr 2006, 148:259-264.
6. Sanders D.B., Hoffman L.R., Emerson J., et al. Return of FEV(1) after pulmonary exacerbation in children with cystic fibrosis. Pediatr Pulmonol 2010, 45:127-134.
7. Liou T.G., Adler F.R., Fitzsimmons S.C., Cahill B.C., Hibbs J.R., Marshall B.C. Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol 2001, 153:345-352.
8. Mayer-Hamblett N., Rosenfeld M., Emerson J., Goss C.H., Aitken M.L. Developing cystic fibrosis lung transplant referral criteria using predictors of 2-year mortality. Am J Respir Crit Care Med 2002, 166:1550-1555.
9. Emerson J., Rosenfeld M., McNamara S., Ramsey B., Gibson R.L. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 2002, 34:91-100.
10. Goss C.H., Burns J.L. Exacerbations in cystic fibrosis. 1: epidemiology and pathogenesis. Thorax 2007, 62:360-367.
11. VanDevanter D.R., Yegin A., Morgan W.J., Millar S.J., Pasta D.J., Konstan M.W. Design and powering of cystic fibrosis clinical trials using pulmonary exacerbation as an efficacy endpoint. J Cyst Fibros 2011, 10:453-459.
12. Wagener J.S., VanDevanter D.R., Regelmann W., et al. Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis. Pediatr Pulmonol Aug 8 2012, [Epub ahead of print]. 10.1002/ppul.22652.
13. Kraynack N.C., Gothard M.D., Falletta L.M., McBride J.T. Approach to treating cystic fibrosis pulmonary exacerbations varies widely across US CF care centers. Pediatr Pulmonol 2011, 46:870-881.
14. Fuchs H.J., Borowitz D.S., Christiansen D.H., et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med 1994, 331:637-642.
15. Quan J.M., Tiddens H.A., Sy J.P., et al. A two-year randomized, placebo controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities. J Pediatr 2001, 139:813-820.
16. Elkins M.R., Robinson M., Rose B.R., et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 2006, 354:229-240.
17. Jaques A., Daviskas E., Turton J.A., et al. Inhaled mannitol improves lung function in cystic fibrosis. Chest 2008, 133:1388-1396.
18. Ramsey B.W., Pepe M.S., Quan J.M., et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 1999, 340:23-30.
19. Murphy T.D., Anbar R.D., Lester L.A., Nasr S.Z., Nickerson B., VanDevanter D.R., et al. Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease. Pediatr Pulmonol 2004, 38:314-320.
20. McCoy K.S., Quittner A.L., Oermann C.M., Gibson R.L., Retsch-Bogart G.Z., Montgomery A.B. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med 2008, 178:921-928.
21. Equi A., Balfour-Lynn I.M., Bush A., Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet 2002, 360:978-984.
22. Wolter J., Seeney S., Bell S., Bowler S., Masel P., McCormack J. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax 2002, 57:212-216.
23. Saiman L., Marshall B.C., Mayer-Hamblett N., et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003, 290:1749-1756.
24. Accurso F.J., Rowe S.M., Clancy J.P., et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med 2010, 363:1991-2003.
25. Ramsey B.W., Davies J., McElvaney N.G., et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011, 365:1663-1672.
26. Konstan M.W., VanDevanter D.R., Rasouliyan L., et al. Trends in the use of routine therapies in cystic fibrosis: 1995-2005. Pediatr Pulmonol 2010, 45:1167-1172.
27. Flume P.A., Mogayzel P.J., Robinson K.A., et al. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med 2009, 180:802-808.
28. Heijerman H., Westerman E., Conway S., Touw D., Döring G., consensus working group Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: a European consensus. J Cyst Fibros 2009, 8:295-315.
29. VanDevanter D.R., Rasouliyan L.H., Murphy T.M., et al. Trends in the clinical characteristics of the U.S. cystic fibrosis patient population from 1995 to 2005. Pediatr Pulmonol 2008, 43:739-744.
30. Cystic Fibrosis Foundation Patient registry 2010. Annual data report to the center directors 2011, Cystic Fibrosis Foundation, Bethesda MD.
31. Morgan W.J., Butler S.M., Johnson C.A., et al. Epidemiologic study of cystic fibrosis: design and implementation of a prospective, multicenter, observational study of patients with cystic fibrosis in the U.S. and Canada. Pediatr Pulmonol 1999, 28:231-241.
32. Rabin H.R., Butler S.M., Wohl M.E., et al. Pulmonary exacerbations in cystic fibrosis. Pediatr Pulmonol 2004, 37:400-406.